Corticotropin

Generic Name: Corticotropin

Brand Names: Acthar, Cortrophin

Drug Type: Biotech

CAS Number: 12427-33-7

Unique Ingredient Identifier: K0U68Q2TXA

Background: Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.

Indication: For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.

Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.

Associated Conditions: Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis

Clinical Trials

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

Not Applicable

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Acthar

First Posted Date: 2014-10-07

Last Posted Date: 2020-09-01

Lead Sponsor: OhioHealth

Target Recruit Count: 30

Registration Number: NCT02258217

Locations: 🇺🇸
OhioHealth, Columbus, Ohio, United States

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Phase 4

Completed

Conditions: Dermatomyositis
Juvenile Dermatomyositis

Interventions: Drug: H.P. Acthar Gel

First Posted Date: 2014-09-22

Last Posted Date: 2024-06-11

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 19

Registration Number: NCT02245841

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

ACTHar in the Treatment of Lupus Nephritis

Phase 4

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: CellCept
Drug: ACTHar gel

First Posted Date: 2014-08-27

Last Posted Date: 2025-03-07

Lead Sponsor: Columbia University

Target Recruit Count: 8

Registration Number: NCT02226341

Locations: 🇺🇸
Columbia University - Herbert Irving Pavilion, New York, New York, United States

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

Phase 4

Conditions: Pulmonary Sarcoidosis
Sarcoidosis

Interventions: Drug: Acthar gel

First Posted Date: 2014-07-11

Last Posted Date: 2015-12-08

Lead Sponsor: University of Cincinnati

Target Recruit Count: 20

Registration Number: NCT02188017

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

Phase 2

Conditions: Hypercalcemia Due to Sarcoidosis
Sarcoidosis

Interventions: Drug: ACTHAR Gel (adrenocorticotropic hormone)

First Posted Date: 2014-06-04

Last Posted Date: 2015-01-26

Lead Sponsor: Albany Medical College

Target Recruit Count: 10

Registration Number: NCT02155803

Locations: 🇺🇸
Albany Medical College, Albany, New York, United States

Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

Phase 3

Completed

Conditions: Nephrotic Syndrome

Interventions: Drug: ACTH

First Posted Date: 2014-05-07

Last Posted Date: 2019-05-29

Lead Sponsor: Emory University

Target Recruit Count: 31

Registration Number: NCT02132195

Locations: 🇺🇸
Pediatric Nephrology of Alabama, PC., Birmingham, Alabama, United States
🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States

and more 13 locations